HC Wainwright reaffirmed their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report sent to investors on Thursday, Marketbeat reports. They currently have a $49.00 price target on the biotechnology company’s stock.
Other research analysts also recently issued research reports about the company. Zacks Investment Research upgraded XOMA from a sell rating to a buy rating and set a $25.00 price target on the stock in a report on Tuesday, October 17th. Wedbush reiterated a buy rating and set a $33.00 price target on shares of XOMA in a report on Tuesday, December 19th. Finally, TheStreet upgraded XOMA from an e+ rating to a c- rating in a report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. XOMA presently has an average rating of Buy and an average price target of $38.33.
Shares of XOMA (NASDAQ:XOMA) traded up $0.43 during trading on Thursday, hitting $33.58. The stock had a trading volume of 191,342 shares, compared to its average volume of 177,730. The firm has a market capitalization of $269.98, a price-to-earnings ratio of -4.68 and a beta of 3.17. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 3.53. XOMA has a 12 month low of $3.96 and a 12 month high of $37.25.
In other news, CEO James R. Neal sold 11,568 shares of XOMA stock in a transaction on Monday, November 13th. The stock was sold at an average price of $30.83, for a total transaction of $356,641.44. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Thomas M. Burns sold 22,222 shares of XOMA stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $28.69, for a total value of $637,549.18. Following the transaction, the senior vice president now owns 13,538 shares in the company, valued at approximately $388,405.22. The disclosure for this sale can be found here. Insiders have sold 87,069 shares of company stock worth $2,517,993 in the last quarter. 3.02% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of Montreal Can purchased a new position in XOMA in the fourth quarter valued at about $138,000. Acadian Asset Management LLC purchased a new position in XOMA in the fourth quarter valued at about $152,000. OxFORD Asset Management LLP purchased a new position in XOMA in the third quarter valued at about $543,000. Finally, EAM Investors LLC purchased a new position in XOMA in the third quarter valued at about $835,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.
WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2018/01/20/xomas-xoma-buy-rating-reaffirmed-at-hc-wainwright.html.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.